Diaceutics PLC 43.9% potential upside indicated by Canaccord Genuity

Diaceutics PLC with ticker (LON:DXRX) now has a potential upside of 43.9% according to Canaccord Genuity.



Canaccord Genuity set a target price of 150 GBX for the company, which when compared to the Diaceutics PLC share price of 104 GBX at opening today (22/03/2024) indicates a potential upside of 43.9%. Trading has ranged between 79 (52 week low) and 110 (52 week high) with an average of 42,038 shares exchanging hands daily. The market capitalisation at the time of writing is £88,296,393.

Diaceutics PLC is a United Kingdom-based company, which is a provider of technology and solutions. The Company provides pharma and biotech companies with an end-to-end commercialization solution for precision medicine through data analytics, scientific and advisory services enabled by its platform DXRX – The Diagnostics Network. The Company operates through three segments: Insight Solutions (Data), Engagement Solutions (Tech enabled services), and Advisory Services (Professional services). The Company’s DXRX – The Diagnostics Network is a diagnostic commercialization platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories. It provides unrivalled access to multiple pipelines of real-world diagnostic testing data from a global network of laboratories. Its Tech Enabled Services offers clinical testing labs to provide enablement and educational services in novel biomarkers.